RNAi therapeutic and its innovative biotechnological evolution
Abstract Recently, United States Food and Drug Administration (FDA) and European
Commission (EC) approved Alnylam Pharmaceuticals' RNA interference (RNAi) therapeutic …
Commission (EC) approved Alnylam Pharmaceuticals' RNA interference (RNAi) therapeutic …
Lipid delivery systems for nucleic-acid-based-drugs: From production to clinical applications
AA Barba, S Bochicchio, A Dalmoro, G Lamberti - Pharmaceutics, 2019 - mdpi.com
In the last years the rapid development of Nucleic Acid Based Drugs (NABDs) to be used in
gene therapy has had a great impact in the medical field, holding enormous promise …
gene therapy has had a great impact in the medical field, holding enormous promise …
Longitudinal analysis of the human B cell response to Ebola virus infection
Ebola virus (EBOV) remains a public health threat. We performed a longitudinal study of B
cell responses to EBOV in four survivors of the 2014 West African outbreak. Infection …
cell responses to EBOV in four survivors of the 2014 West African outbreak. Infection …
Ebola virus: pathogenesis and countermeasure development
W Furuyama, A Marzi - Annual review of virology, 2019 - annualreviews.org
Since its discovery in 1976, Ebola virus (EBOV) has caused numerous outbreaks of fatal
hemorrhagic disease in Africa. The biggest outbreak on record is the 2013–2016 epidemic …
hemorrhagic disease in Africa. The biggest outbreak on record is the 2013–2016 epidemic …
Perspectives towards antiviral drug discovery against Ebola virus
Ebola virus disease (EVD), caused by Ebola viruses, resulted in more than 11 500 deaths
according to a recent 2018 WHO report. With mortality rates up to 90%, it is nowadays one of …
according to a recent 2018 WHO report. With mortality rates up to 90%, it is nowadays one of …
Anti-Ebola therapy for patients with Ebola virus disease: a systematic review
JS Lee, NKJ Adhikari, HY Kwon, K Teo… - BMC infectious …, 2019 - Springer
Abstract Background Management of Ebola virus disease (EVD) has historically focused on
infection prevention, case detection and supportive care. Several specific anti-Ebola …
infection prevention, case detection and supportive care. Several specific anti-Ebola …
Ebola virus disease: clinical challenges, recognition, and management
EL Beam, MM Schwedhelm, KC Boulter… - Nursing …, 2019 - nursing.theclinics.com
The epidemic of Ebola virus disease (EVD) in West Africa that began in 2013 was the
world's 25th known outbreak of the disease, dwarfing, in numbers of cases, the previous 24 …
world's 25th known outbreak of the disease, dwarfing, in numbers of cases, the previous 24 …
Controlling protein expression by delivery of RNA therapeutics using lipid nanoparticles
PJC Lin, YK Tam - Nucleic Acid Nanotheranostics, 2019 - Elsevier
Dysregulated protein expression is the basis for a wide variety of diseases ranging from
cancer to metabolic diseases. The ability to normalize protein levels, by introducing either …
cancer to metabolic diseases. The ability to normalize protein levels, by introducing either …
Evaluating promising investigational medical countermeasures: recommendations in the absence of guidelines
Emerging and re-emerging infectious diseases pose growing global public health threats.
However, research on and development of medical countermeasures (MCMs) for such …
However, research on and development of medical countermeasures (MCMs) for such …
Caring for patients with Ebola virus disease: Are US biocontainment centers ready for the next outbreak?
CL Dean, CE Hill - Seminars in Diagnostic Pathology, 2019 - Elsevier
Abstract The 2014 West African Ebola virus disease (EVD) outbreak is the largest and
deadliest EVD epidemic to date, resulting in fivefold more cases than all other outbreaks …
deadliest EVD epidemic to date, resulting in fivefold more cases than all other outbreaks …